Advertisement

Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study

  • Min Li
  • Hua Zhou
  • Min Yang
  • Changying Xing
Nephrology - Original Paper
  • 11 Downloads

Abstract

Purpose

Vascular calcification (VC) is known to be prevalent in patients with end-stage renal disease (ESRD). Sclerostin has been identified to be involved in the cross-talk between the kidney, vasculature, and bone. The aims of the present study were to evaluate vessel sclerostin expression and its correlation with VC, as well as serum sclerostin levels.

Methods

A total of 51 adult ESRD patients undergoing living donor renal transplant (RT) were enrolled in this study. Serum sclerostin levels were measured by enzyme-linked immunosorbent assays. The thoracic aorta calcification (TAC) was measured by computed tomography (CT). The aortic calcification area index (ACAI) was used to evaluate the severity of TAC. During the RT surgery, the internal iliac arteries were collected and paraffin-embedded in 40 patients, followed by immunohistochemical staining for sclerostin expression and von Kossa-staining for vascular medial calcification degree.

Results

The prevalence rate of TAC detected by CT was 58.82%. The positive rates of the internal iliac arterial calcification and vessel sclerostin expression were both 45%. Vessel sclerostin was strongly co-localized with medial calcification. Multivariate analyses revealed that only serum sclerostin was significantly associated with the presence of TAC, the severity of TAC and the positive expression of vessel sclerostin. Kappa test showed that the consistency of the two different calcification assessment methods, as well as the consistency of vessel sclerostin expression and von Kossa-staining were high. Furthermore, the cutoff points of serum sclerostin for vessel sclerostin expression, the presence of VC evaluated by CT and that evaluated by pathology were 1599.92 pg/mL, 2475.52 pg/mL, and 2116.23 pg/mL, respectively.

Conclusions

The two methods, namely CT and pathology, to evaluate VC were highly consistent. Serum sclerostin was an independent determinant of positive expression of vessel sclerostin and VC in ESRD patients eligible for RT.

Keywords

End-stage renal disease Vessel sclerostin Serum sclerostin Vascular calcification 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual part in the study.

References

  1. 1.
    Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI, Investigators CS (2011) Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 58(4):519–526.  https://doi.org/10.1053/j.ajkd.2011.04.024 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lewiecki EM (2014) Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis 6(2):48–57.  https://doi.org/10.1177/1759720x13510479 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D’Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28(12):3024–3030.  https://doi.org/10.1093/ndt/gft039 CrossRefPubMedGoogle Scholar
  4. 4.
    Zhu D, Mackenzie NC, Millan JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595.  https://doi.org/10.1371/journal.pone.0019595 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228.  https://doi.org/10.1210/jc.2013-1521 CrossRefPubMedGoogle Scholar
  6. 6.
    Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R, Marx N, Kramann R (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 22(3):317–325PubMedGoogle Scholar
  7. 7.
    Didangelos A, Yin X, Mandal K, Baumert M, Jahangiri M, Mayr M (2010) Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteom MCP 9(9):2048–2062.  https://doi.org/10.1074/mcp.M110.001693 CrossRefGoogle Scholar
  8. 8.
    Brandenburg VM, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219.  https://doi.org/10.1186/1471-2369-14-219 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lv W, Guan L, Zhang Y, Yu S, Cao B, Ji Y (2016) Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 48(12):2043–2050.  https://doi.org/10.1007/s11255-016-1379-8 CrossRefPubMedGoogle Scholar
  10. 10.
    Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Soderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356–1364.  https://doi.org/10.1038/ki.2015.194 CrossRefPubMedGoogle Scholar
  11. 11.
    Morena M, Jaussent I, Dupuy AM, Bargnoux AS, Kuster N, Chenine L, Leray-Moragues H, Klouche K, Vernhet H, Canaud B, Cristol JP (2015) Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 30(8):1345–1356.  https://doi.org/10.1093/ndt/gfv081 CrossRefPubMedGoogle Scholar
  12. 12.
    Pelletier S, Confavreux CB, Haesebaert J, Guebre-Egziabher F, Bacchetta J, Carlier MC, Chardon L, Laville M, Chapurlat R, London GM, Lafage-Proust MH, Fouque D (2015) Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int 26 (8):2165–2174.  https://doi.org/10.1007/s00198-015-3127-9 CrossRefPubMedGoogle Scholar
  13. 13.
    Wang XR, Yuan L, Zhang JJ, Hao L, Wang DG (2017) Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrology 22(4):286–292.  https://doi.org/10.1111/nep.12813 CrossRefPubMedGoogle Scholar
  14. 14.
    Yang CY, Chang ZF, Chau YP, Chen A, Yang WC, Yang AH, Lee OK (2015) Circulating Wnt/beta-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 30(8):1356–1363.  https://doi.org/10.1093/ndt/gfv043 CrossRefPubMedGoogle Scholar
  15. 15.
    Jean G, Chazot C, Bresson E, Zaoui E, Cavalier E (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132(3):181–190.  https://doi.org/10.1159/000443845 CrossRefPubMedGoogle Scholar
  16. 16.
    Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669–4676.  https://doi.org/10.1210/jc.2015-3056 CrossRefPubMedGoogle Scholar
  17. 17.
    Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4(5893):643–646CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Thomas IC, McClelland RL, Michos ED, Allison MA, Forbang NI, Longstreth WT Jr, Post WS, Wong ND, Budoff MJ, Criqui MH (2017) Density of calcium in the ascending thoracic aorta and risk of incident cardiovascular disease events. Atherosclerosis 265:190–196.  https://doi.org/10.1016/j.atherosclerosis.2017.09.009 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Craiem D, Chironi G, Casciaro ME, Graf S, Simon A (2014) Calcifications of the thoracic aorta on extended non-contrast-enhanced cardiac CT. PLoS ONE 9(10):e109584.  https://doi.org/10.1371/journal.pone.0109584 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Takasu J, Budoff MJ, O’Brien KD, Shavelle DM, Probstfield JL, Carr JJ, Katz R (2009) Relationship between coronary artery and descending thoracic aortic calcification as detected by computed tomography: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 204(2):440–446.  https://doi.org/10.1016/j.atherosclerosis.2008.09.041 CrossRefPubMedGoogle Scholar
  21. 21.
    Thomas IC, Thompson CA, Yang M, Allison MA, Forbang NI, Michos ED, McClelland RL, Budoff MJ, Criqui MH (2018) Thoracic aorta calcification and noncardiovascular disease-related mortality: the Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol.  https://doi.org/10.1161/ATVBAHA.118.310850 CrossRefPubMedGoogle Scholar
  22. 22.
    Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, Shigematsu T (2010) Improved assessment of aortic calcification in Japanese patients undergoing maintenance hemodialysis. Int Med 49(19):2071–2075CrossRefGoogle Scholar
  23. 23.
    Sullivan LM, Massaro JM, D’Agostino RB Sr (2004) Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 23(10):1631–1660.  https://doi.org/10.1002/sim.1742 CrossRefPubMedGoogle Scholar
  24. 24.
    Kirkpantur A, Arici M, Altun B, Yilmaz MI, Cil B, Aki T, Bakkaloglu M, Turgan C (2008) Association of serum lipid profile and arteriovenous fistula thrombosis in maintenance hemodialysis patients. Blood Purif 26(4):322–332.  https://doi.org/10.1159/000132388 CrossRefPubMedGoogle Scholar
  25. 25.
    Patsalas S, Eleftheriadis T, Spaia S, Theodoroglou H, Antoniadi G, Liakopoulos V, Passadakis P, Vayonas G, Vargemezis V (2007) Thirty-month follow-up of coronary artery calcification in hemodialysis patients: different roles for inflammation and abnormal calcium-phosphorous metabolism? Ren Fail 29(5):623–629.  https://doi.org/10.1080/08860220701395010 CrossRefPubMedGoogle Scholar
  26. 26.
    Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M, Chronic Renal Insufficiency Cohort Study Investigators (2013) Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83(6):1159–1168.  https://doi.org/10.1038/ki.2013.3 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa T (2014) Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 85(5):1103–1111.  https://doi.org/10.1038/ki.2013.332 CrossRefPubMedGoogle Scholar
  28. 28.
    Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA, European Uremic Toxin Work Group (2012) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23(7):2017–2025.  https://doi.org/10.1007/s00198-011-1838-0 CrossRefPubMedGoogle Scholar
  29. 29.
    Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL, Naves-Diaz M, Ruiz-Torres MP, Cannata-Andia JB (2010) High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46(1):121–128.  https://doi.org/10.1016/j.bone.2009.09.006 CrossRefPubMedGoogle Scholar
  30. 30.
    Patsalas S, Eleftheriadis T, Spaia S, Theodoroglou H, Panou E, Liakopoulos V, Antoniadi G, Passadakis P, Vayonas G, Kanakis E, Vargemezis V (2005) The value of computed tomography-derived coronary artery calcification score in coronary artery disease detection in asymptomatic hemodialysis patients. Ren Fail 27(6):683–688CrossRefPubMedGoogle Scholar
  31. 31.
    Kirkpantur A, Balci M, Turkvatan A, Afsar B (2016) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 36(1):24–32.  https://doi.org/10.1016/j.nefro.2015.07.006 CrossRefPubMedGoogle Scholar
  32. 32.
    Balci M, Kirkpantur A, Turkvatan A, Mandiroglu S, Ozturk E, Afsar B (2015) Sclerostin as a new key player in arteriovenous fistula calcification. Herz 40(2):289–297.  https://doi.org/10.1007/s00059-013-3992-y CrossRefPubMedGoogle Scholar
  33. 33.
    Zeng C, Guo C, Cai J, Tang C, Dong Z (2018) Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diabetes Vasc Dis Res 15(2):99–105.  https://doi.org/10.1177/1479164117742316 CrossRefGoogle Scholar
  34. 34.
    Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL (2002) A role for the beta-catenin/T-cell factor signaling cascade in vascular remodeling. Circ Res 90(3):340–347CrossRefPubMedGoogle Scholar
  35. 35.
    Wang X, Adhikari N, Li Q, Hall JL (2004) LDL receptor-related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 287(6):H2376–H2383.  https://doi.org/10.1152/ajpheart.01173.2003 CrossRefPubMedGoogle Scholar
  36. 36.
    Kanbay M, Solak Y, Siriopol D, Aslan G, Afsar B, Yazici D, Covic A (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042.  https://doi.org/10.1007/s11255-016-1387-8 CrossRefPubMedGoogle Scholar
  37. 37.
    Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol CJASN 8(5):819–823.  https://doi.org/10.2215/cjn.07670712 CrossRefPubMedGoogle Scholar
  38. 38.
    Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90(6):473–480.  https://doi.org/10.1007/s00223-012-9595-4 CrossRefPubMedGoogle Scholar
  39. 39.
    Zhou H, Yang M, Li M, Cui L (2017) Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. Int Urol Nephrol 49(8):1433–1437.  https://doi.org/10.1007/s11255-017-1604-0 CrossRefPubMedGoogle Scholar
  40. 40.
    Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248–255.  https://doi.org/10.1210/jc.2013-2786 CrossRefPubMedGoogle Scholar
  41. 41.
    Confavreux CB (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int Suppl.  https://doi.org/10.1038/ki.2011.25 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kogawa M, Wijenayaka AR, Ormsby RT, Thomas GP, Anderson PH, Bonewald LF, Findlay DM, Atkins GJ (2013) Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res 28(12):2436–2448.  https://doi.org/10.1002/jbmr.2003 CrossRefPubMedGoogle Scholar
  43. 43.
    Brandenburg VM, D’Haese P, Deck A, Mekahli D, Meijers B, Neven E, Evenepoel P (2016) From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. Pediatr Nephrol 31(2):195–206.  https://doi.org/10.1007/s00467-015-3069-7 CrossRefPubMedGoogle Scholar
  44. 44.
    Baek K, Hwang HR, Park HJ, Kwon A, Qadir AS, Ko SH, Woo KM, Ryoo HM, Kim GS, Baek JH (2014) TNF-alpha upregulates sclerostin expression in obese mice fed a high-fat diet. J Cell Physiol 229(5):640–650.  https://doi.org/10.1002/jcp.24487 CrossRefPubMedGoogle Scholar
  45. 45.
    Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH (2011) Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol CJASN 6(4):877–882.  https://doi.org/10.2215/CJN.06550810 CrossRefPubMedGoogle Scholar
  46. 46.
    Drake MT, Khosla S (2017) Hormonal and systemic regulation of sclerostin. Bone 96:8–17.  https://doi.org/10.1016/j.bone.2016.12.004 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Department of NephrologyThe First Affiliated Hospital of Nanjing Medical University, Jiangsu Province HospitalNanjingChina
  2. 2.Department of NephrologyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina

Personalised recommendations